GlaxoSmithKline plc Q3 2026 Earnings Recap

GSK shares fell 5.7% after earnings. Despite reconfirmed guidance, investors may have been disappointed by the modest 1% growth in core EPS against 5% sales and operating-profit growth; the transcript does not identify a specific cause for the share-price decline.

Key Takeaways

• Q3 sales rose 5% to £8.9 billion; core operating profit grew 5%, while core EPS increased 1%.
• Management reconfirmed 2026 guidance. Cash generation was £7.4 billion year to date, and the Q3 dividend was 17 pence.
• Specialty launches are driving momentum: Jideytro generated £3 million after its first launch, while management cited rising prescriber, patient, and access momentum for Exdensur.
• GSK reported approvals for Jideytro and Hibsago, plus accelerated approval for Jemperli in locally advanced rectal cancer; it also said 18 of 22 planned 2026 Phase III trial starts are recruiting.
• Pipeline data were encouraging, including a 94% response rate for Jideytro in TKI-naive patients and a 61% response rate for Ris-Rez in a global small-cell lung cancer cohort; these are clinical data, not reported sales.